PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials
Abstract Background Ovarian cancer is the eighth leading cause of cancer-related death among women, characterized by late diagnosis and a high relapse rate. In randomized controlled trials, we aimed to evaluate the efficacy and safety of PARP inhibitors (PARPi) in treating advanced ovarian cancer. M...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-02-01
|
Series: | Journal of Ovarian Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13048-024-01362-y |